Articles tagged with Cancer Immunology
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
A Phase 1 clinical trial found that an investigational CAR-T therapy, anito-cel, led to high response rates and durable benefits in patients with relapsed/refractory multiple myeloma. Serious side effects were uncommon, and no delayed neurological complications were reported.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
Researchers found similar diarrhea outcomes among patients with low and normal fecal elastase levels, suggesting stool dilution is a possible cause. Fecal fat testing is recommended before enzyme therapy to confirm exocrine pancreatic insufficiency.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Researchers from City of Hope have developed a 'plug-and-play' CAR T technology that allows scientists to update engineered cancer-fighting immune cells after treatment. This technology, called meditope, enables the cells to adapt as tumors evolve, helping them to better control the cells and redirect them to attack different types of ...
The Alliance for Clinical Trials in Oncology is hosting a public webinar highlighting key findings from Alliance and Alliance Foundation Trials studies presented at the 2026 ASCO Annual Meeting. The webinar will feature treatment advances for breast, lung, and prostate cancers, and will include patient representatives to provide insigh...
Researchers develop nanoparticles that target tumor-associated macrophages, reprogramming them to attract cancer-fighting T cells. The approach shows promise in reducing immune-suppressing macrophages and increasing cancer-fighting T cells, with potential for improving immunotherapy for solid cancers.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
Researchers found that longer-lived bats have higher levels of cancer-fighting genes and an immune system that can mount an overwhelming attack against infectious organisms and cancer. This discovery suggests that understanding one will help scientists understand the other.
Researchers have developed an mRNA immunotherapy that eliminates pancreatic tumors in mice, achieving complete tumor responses and long-term disease-free periods. The treatment uses a cocktail of immune cytokine and tumor-associated antigen mRNAs, showing promise as a potential transformative treatment for pancreatic cancer.
Researchers from the University of Osaka have found a rare type of immune cell that expands in supercentenarians, potentially helping protect against cancer and other age-related threats. The cells, known as CD4 CTLs, have been shown to be highly active and may help the body cope with persistent threats that increase with age.
Researchers found that tumors can damage peripheral nerves before chemotherapy begins, leading to potential nerve damage and chronic pain. The study challenges the conventional thought that peripheral neuropathy is mostly due to chemotherapy treatment.
The Alliance for Clinical Trials in Oncology emphasizes the significance of clinical trials in advancing breast cancer treatments and early detection. The organization's work has led to a 44% decline in breast cancer mortality rates among women since 1989.
Researchers identify IL-26 as a key regulator that reprograms tumor cells to evade immune attack, promoting immune escape and resistance to anti-PD-1 therapy. Targeting IL-26 may improve immunotherapy outcomes and lead to new treatments for cancer and chronic inflammatory diseases.
Researchers at Pusan National University investigated how chronic environmental stress drives immune dysfunction in cold tumors, revealing a key driver of NK-cell maladaptation: the GDF15-AhR axis. This axis sustains activation of stress-sensing receptors, gradually exhausting NK cells and enabling immune escape.
Research at UT MD Anderson Cancer Center has identified biomarkers to identify patients with resectable NSCLC who benefit most from perioperative immunotherapy. The center also found that the composition of donor cord blood may influence CAR NK cell therapy outcomes.
Recent research found that D-serine accelerates gastric cancer growth by suppressing cytotoxic T-cell activity and promoting immunosuppressive macrophages. High serum D-serine concentrations were linked to ICI therapy resistance in patients, suggesting its potential as a biomarker for disease progression.
Cancer cells' ability to evade the immune system is linked to changes in their surrounding environment, including nearby nutrients and conditions. Researchers discovered that altering these factors can thin the cancer cell's protective sugar coating, allowing the immune system to recognize and eliminate them.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center are developing drug-based strategies to enhance cancer immunotherapy for melanoma and potentially other cancers. They identified two promising compounds that could strengthen T cell interaction with cancer cells or make tumor cells more susceptible to destruction by T cells.
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
Researchers found that chemotherapy triggers an inflammatory cascade recruiting immune cells to protect the tumor, leading to chemoresistance. Blocking this pathway with existing drugs may restore chemotherapy sensitivity.
Researchers discover how tumors hijack the thymus to evade immune surveillance by transporting tumor antigens there. Disrupting a specific chemokine receptor may enhance anti-tumor immunity and improve cancer treatment outcomes.
A new study reveals that p53 mutations in cancer cells can limit the effectiveness of immunotherapy by manipulating cellular metabolism, specifically through autophagy. Removing these mutant forms of p53 restores mTORC1 activity and reduces autophagy, making tumors more vulnerable to immune attack.
Scientists at UVA have developed a new method to target glioblastoma, the most common and deadly brain cancer, by delivering microRNAs through the brain's natural barrier. The approach shows promise in slowing tumor growth and extending survival in animal models.
A study published in Cancer Research identified an immune pathway that promotes the progression of oral precancerous lesions into head and neck squamous cell carcinoma. The researchers found that targeting a key inflammation signal known as interleukin-1 alpha (IL-1α) could help restore immune surveillance and prevent high-risk lesions...
A study published in Science reveals that dendritic cells build and maintain structures called tertiary lymphoid structures (TLSs) within tumors, which serve as local command centers for the immune system. These hubs play a key role in antitumor immunity and may be a target for future therapies.
Researchers at UT MD Anderson Cancer Center have made significant progress in treating rare brain infections with a virus-specific T cell therapy, achieving an overall response rate of 56.8% in patients with progressive multifocal leukoencephalopathy (PML). The center also introduced a novel CAR T cell therapy for hard-to-treat kidney ...
The emerging role of ZBP1 in cancer therapy involves converting genomic stress into potent antitumor immunity. Therapeutic activation of the ZBP1 pathway may transform immunologically "cold" tumors into "hot" tumors by inducing immunogenic necroptosis, stimulating robust immune responses.
Sylvester researchers develop AI-powered fracture prediction models, train as wildland firefighters to reduce cancer risk, and discover new targets for pancreatic cancer treatment. A new tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells.
Scientists at MD Anderson Cancer Center have identified a previously unknown mechanism by which T cells attack and eliminate acute myeloid leukemia (AML) cells. The discovery reveals that AML cells use a CD64-dependent pathway to evade traditional MHC recognition, potentially explaining why AML is sensitive to immune-based treatments.
A buildup of bile acids caused by an unhealthy gut can drive breast cancer to other parts of the body, researchers reveal. The study found that replenishing beneficial bacteria or treating patients with FDA-approved bile acid sequestrants may reduce breast cancer metastasis.
Researchers created a comprehensive single-cell map of the tumor immune microenvironment in multiple myeloma and its precursor conditions. The study identified five distinct subtypes, or 'ecotypes,' that capture meaningful insights into signaling pathways and genetic programs not fully explained by disease stage alone.
A multidisciplinary consensus updates treatment guidance for prolactinomas, emphasizing early recognition, individualized management strategies, and advanced imaging. The recommendations cover screening, assessment, diagnosis, treatment, and long-term monitoring to improve patient outcomes and quality of life.
A study published in Cancer Cell identified a six-gene signature in microscopic colorectal cancer liver metastases that may help predict recurrence after treatment. The findings suggest these tiny tumor deposits could serve as a tissue-based marker of residual cancer cells, recurrence risk and chemotherapy resistance.
Researchers found that yeast-based supplements can reprogram early-stage immune cells to produce enhanced anti-tumor responses. The study suggests a potential solution for obesity-related immune dysfunction and cancer, using a food-grade supplement with an excellent safety record.
A new method called ATTACH identifies strong interactions between T cells and cancer-specific proteins to isolate effective tumor-reactive T cells. This approach overcomes key challenges in immunotherapy development, offering a rapid and accessible way for isolating rare immune cells.
The new journal features cutting-edge research across basic, clinical, and translational immunology. It is designed to connect researchers across the full breadth of immunology, deepening understanding of the immune system in health and disease.
Researchers developed a strategy to attack glioblastoma on two fronts by targeting the tumour and its immune support system. In preclinical models, the therapy eliminated detectable tumours and led to long-term disease-free survival.
Researchers at the University of Turku have developed a reliable laboratory model to study BAP1-deficient melanomas, which are resistant to immunotherapies. The new tool could lead to novel immunotherapy combinations for aggressive melanomas.
Scientists from the University of Osaka have identified a previously unknown molecular mechanism linking mitochondrial morphology to innate immune activation. Abnormally long mitochondria can trigger the release of mitochondrial RNA into the cytosol, activating RNA-sensing proteins and leading to anti-tumor immunity.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Researchers will develop genetic boosters and "two-factor authentication" for CAR T cell therapy, targeting HER2-positive lung, breast, and colon tumors. The project aims to improve the efficacy of CAR T cells against solid tumors while reducing collateral damage.
Scientists have identified a unique chimeric RNA called UBA1-CDK16 that plays important roles in women's blood cell development and disease severity. The findings suggest the chimeric RNA may serve as a natural brake to protect women from excessive autoimmune activity.
The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced the selection of five early-career scientists to pursue four-year grants in cancer research. The scholars will investigate big questions about cancer development, diagnosis, and treatment.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Rice University has received a $2 million CPRIT award to advance cancer research, including new studies in immunotherapy and ovarian cancer. The funding will support the expansion of the Genetic Design and Engineering Center, which provides a centralized hub for DNA tools used in cancer research.
Researchers at UT MD Anderson Cancer Center have made significant advances in understanding cancer biology, developing AI-powered atlas of tertiary lymphoid structures as prognostic biomarkers, and uncovering drivers of resistance to KRAS inhibitors. Additionally, they have discovered a molecular pathway that drives stressed cells to b...
Activated memory B cells can recognize and target ovarian cancer cells, producing effective antibodies. The discovery advances the development of vaccines and therapies based on immune memory against cancer.
Researchers found that smaller tetraploid cancer cells are more aggressive and tumorigenic, associated with worse prognosis and lower survival rates in several cancer types. This discovery challenges the conventional understanding of tetraploidy's role in cancer progression.
A new cytokine-armored CAR-T cell therapy has been developed to attack aggressive brain tumors in mice while reducing side effects. The approach recruits the body's immune system using IL-12 and DR-18 proteins, strengthening the anti-cancer response and improving tumor control.
A new mRNA-based strategy amplifies the T-cell response to vaccines, enabling more powerful cancer vaccines and stronger protection against infectious diseases. The approach reprograms immune cells from within using mRNA instructions that expand cancer-fighting T cells.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
Dr. Marcus Ruscetti receives the prize to study senescence and its impact on immune responses in cancer metastasis. The funding will help him develop novel treatments targeting senescent cells.
A personalized vaccine has been shown to be safe and effective in treating glioblastoma, a fast-growing brain cancer. The vaccine elicited robust and broad immune responses that appeared to increase recurrence-free survival in patients after surgery.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Researchers found that patients with high senescence burdens in their CD8+ T cells were more likely to fail treatment, while those with youthful profiles responded better. The study identified three transcription factors controlling the senescence program, which can be targeted to improve treatment outcomes.